Agile Therapeutics Inc (NASDAQ:AGRX) has earned a consensus recommendation of “Buy” from the seven brokerages that are covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $4.00.
Several research analysts have recently issued reports on AGRX shares. HC Wainwright set a $4.00 target price on shares of Agile Therapeutics and gave the stock a “buy” rating in a report on Monday, May 21st. Royal Bank of Canada cut their target price on shares of Agile Therapeutics to $3.00 and set an “outperform” rating on the stock in a report on Monday, May 21st. Finally, ValuEngine upgraded shares of Agile Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 1st.
Shares of Agile Therapeutics stock opened at $0.36 on Friday. Agile Therapeutics has a 52-week low of $0.23 and a 52-week high of $5.40. The company has a market capitalization of $18.91 million, a PE ratio of -0.40 and a beta of 1.47.
Agile Therapeutics (NASDAQ:AGRX) last issued its earnings results on Friday, August 3rd. The specialty pharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.01. research analysts forecast that Agile Therapeutics will post -0.61 EPS for the current fiscal year.
In related news, insider Life Sciences Maste Perceptive sold 298,628 shares of Agile Therapeutics stock in a transaction on Thursday, July 26th. The shares were sold at an average price of $0.30, for a total value of $89,588.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 7.30% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in AGRX. Franklin Resources Inc. boosted its holdings in Agile Therapeutics by 17.0% in the first quarter. Franklin Resources Inc. now owns 3,355,200 shares of the specialty pharmaceutical company’s stock valued at $8,623,000 after acquiring an additional 487,400 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Agile Therapeutics by 76.3% in the second quarter. Renaissance Technologies LLC now owns 792,990 shares of the specialty pharmaceutical company’s stock valued at $392,000 after acquiring an additional 343,290 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Agile Therapeutics by 62.8% in the first quarter. Dimensional Fund Advisors LP now owns 145,070 shares of the specialty pharmaceutical company’s stock valued at $373,000 after acquiring an additional 55,937 shares in the last quarter. Finally, A.R.T. Advisors LLC boosted its holdings in Agile Therapeutics by 82.3% in the first quarter. A.R.T. Advisors LLC now owns 66,426 shares of the specialty pharmaceutical company’s stock valued at $170,000 after acquiring an additional 29,995 shares in the last quarter. Institutional investors and hedge funds own 52.00% of the company’s stock.
About Agile Therapeutics
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.
Featured Article: Investing in Dividend Stocks
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.